Literature DB >> 23689716

MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.

Jennifer Steele1, Quanshun Zhang, Gillian Beamer, Michelle Butler, Terry Bowlin, Saul Tzipori.   

Abstract

The novel antibiotic MBX-500, dosed at 100, 200, or 400 mg/kg twice daily for 7 days, was evaluated for the treatment of Clostridium difficile infection (CDI) in the gnotobiotic pig model. MBX-500 increased survival at all doses and at high doses improved clinical signs and reduced lesion severity, similar to vancomycin. Our results show that MBX-500 is an effective antibiotic for the treatment of diarrhea associated with CDI and prevents severe systemic disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23689716      PMCID： PMC3719748          DOI： 10.1128/AAC.00304-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Detection, treatment, and prevention of Clostridium difficile infection.

Authors:  David L McCollum; J Martin Rodriguez
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-17       Impact factor: 11.382

Review 3.  Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

Authors:  Jason W Lancaster; S James Matthews
Journal:  Clin Ther       Date:  2012-01       Impact factor: 3.393

4.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

5.  Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

Authors:  Laurica A Petrella; Susan P Sambol; Adam Cheknis; Kristin Nagaro; Yin Kean; Pamela S Sears; Farah Babakhani; Stuart Johnson; Dale N Gerding
Journal:  Clin Infect Dis       Date:  2012-04-20       Impact factor: 9.079

6.  An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins.

Authors:  Xiangyun He; Jufang Wang; Jennifer Steele; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  J Microbiol Methods       Date:  2009-04-23       Impact factor: 2.363

7.  Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing.

Authors:  George Killgore; Angela Thompson; Stuart Johnson; Jon Brazier; Ed Kuijper; Jacques Pepin; Eric H Frost; Paul Savelkoul; Brad Nicholson; Renate J van den Berg; Haru Kato; Susan P Sambol; Walter Zukowski; Christopher Woods; Brandi Limbago; Dale N Gerding; L Clifford McDonald
Journal:  J Clin Microbiol       Date:  2007-11-26       Impact factor: 5.948

Review 8.  Treatment of Clostridium difficile infection.

Authors:  Dale N Gerding; Carlene A Muto; Robert C Owens
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

9.  Piglet models of acute or chronic Clostridium difficile illness.

Authors:  Jennifer Steele; Hanping Feng; Nicola Parry; Saul Tzipori
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

Review 10.  Burden of Clostridium difficile on the healthcare system.

Authors:  Erik R Dubberke; Margaret A Olsen
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079
  10 in total
  4 in total

1.  Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.

Authors:  Hyeun Bum Kim; Quanshun Zhang; Xingmin Sun; Gillian Beamer; Yuankai Wang; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

Review 2.  DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.

Authors:  Erika van Eijk; Bert Wittekoek; Ed J Kuijper; Wiep Klaas Smits
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

Review 3.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 4.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.